BioMarin to Participate in Two Upcoming Virtual Investor Conferences
BioMarin Pharmaceutical (NASDAQ: BMRN) has announced its participation in two upcoming virtual investor conferences. An audio webcast of these presentations will be available live, with access provided through the company's investor relations website. Additionally, an archived version will be accessible for a limited time post-conference. BioMarin specializes in innovative therapies for serious rare disorders, boasting a portfolio of six commercialized products along with several candidates in clinical stages.
- None.
- None.
SAN RAFAEL, Calif., Jan. 5, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: | |
Investors | Media |
Traci McCarty | Debra Charlesworth |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (415) 455-7451 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-301200463.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
What conferences will BioMarin participate in January 2021?
How can I access BioMarin's conference webcasts?
Where can I find archived presentations from BioMarin's investor conferences?
What is BioMarin Pharmaceutical's core focus?